Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients
with differentiated thyroid cancer that has spread to other places in the body or has come
back and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread.